Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ANRO declined for three days, in 105 of 129 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
ANRO moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANRO crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for ANRO entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 150 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
ANRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.771) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XPH declined for three days, in 232 of 277 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
The 10-day moving average for XPH crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for XPH entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XPH's RSI Indicator exited the oversold zone, 18 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in 278 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
XPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
| ANRO | XPH | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Stochastic ODDS (%) | 5 days ago 90% | 1 day ago 81% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| Advances ODDS (%) | 8 days ago 88% | 8 days ago 86% |
| Declines ODDS (%) | 3 days ago 81% | 3 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 87% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANRO’s FA Score shows that 0 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANRO’s TA Score shows that 4 TA indicator(s) are bullish.
ANRO (@Biotechnology) experienced а -9.97% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
ANRO is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NERV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NERV could also see price increases.
| Ticker / NAME | Correlation To ANRO | 1D Price Change % | ||
|---|---|---|---|---|
| ANRO | 100% | -3.01% | ||
| NERV - ANRO | 51% Loosely correlated | -2.89% | ||
| CELC - ANRO | 41% Loosely correlated | -6.17% | ||
| PRAX - ANRO | 38% Loosely correlated | -2.61% | ||
| IMTX - ANRO | 37% Loosely correlated | -5.74% | ||
| SPRB - ANRO | 37% Loosely correlated | -4.39% | ||
More | ||||
A.I.dvisor indicates that over the last year, XPH has been loosely correlated with NUVB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if XPH jumps, then NUVB could also see price increases.
| Ticker / NAME | Correlation To XPH | 1D Price Change % | ||
|---|---|---|---|---|
| XPH | 100% | -1.87% | ||
| NUVB - XPH | 46% Loosely correlated | -6.32% | ||
| ELAN - XPH | 44% Loosely correlated | +0.04% | ||
| ROIV - XPH | 43% Loosely correlated | -1.50% | ||
| ANRO - XPH | 42% Loosely correlated | -3.01% | ||
| PLRX - XPH | 40% Loosely correlated | -7.46% | ||
More | ||||